Sermorelin vs ipamorelin: two different signals

The difference begins at the receptor

The difference between sermorelin and ipamorelin is not simply a difference in strength. Sermorelin is a GHRH analog acting at the GHRH receptor. Ipamorelin belongs to the GHRP class acting at the ghrelin/GHS receptor. Both sit within the regulation of growth hormone, but they begin with different signals. The GHRH review and the review of peptide drugs in sport provide the wider pharmacological context.

I’m unconvinced by comparisons that turn a receptor distinction into a recommendation. A receptor is the cell’s receiving site, not a score for how much better a person will sleep or function. The relevant question is which drug was tested, in whom, against what comparator and for which outcome.

Ipamorelin or sermorelin? The empty comparison column

There is no direct sermorelin-versus-ipamorelin clinical outcome trial in the papers listed here. Sermorelin’s pediatric growth finding and older-men GH/IGF-1 finding give it a particular record. They do not supply the missing comparison arm.

I’d call this comparison unfinished: the evidence cannot name a winner for sleep, strength, weight or long-term safety. Even the argument that sermorelin’s feedback regulation is more physiologic comes from an editorial rationale, rather than a head-to-head outcome result. That leaves useful biology and a substantial unanswered comparison.

A larger GH rise would still leave work to do

Different inputs make combination experiments plausible. But the cited pediatric comparison used GHRH(1-29NH2), GHRP-2 and their combination. Responses differed between children with GH insufficiency and those with idiopathic short stature. That is the actual study population and actual second peptide.

It is not a trial demonstrating that sermorelin plus ipamorelin improves adult health. The recent sports-medicine review leaves GH-axis secretagogues with uncertain efficacy and safety for those uses. I’m wary of ‘synergy’ when the word travels further than the outcome data.

Tesamorelin belongs closer on the family tree

The similarity of names can obscure a more useful comparison.

Sermorelin vs tesamorelin

Both are GHRH analogs; tesamorelin is stabilized to last longer. In the controlled trial of 152 older adults, including 66 with mild cognitive impairment, 20 weeks of tesamorelin produced a favorable cognitive effect, with IGF-1 up 117% within the physiologic range and percent body fat down 7.4%.

Those are tesamorelin findings. Comparing ipamorelin vs sermorelin cannot absorb them into either drug’s evidence column. The drug name in a trial is part of its result.

And hexarelin vs ipamorelin?

That search introduces another comparison. None of the cited studies here establishes a clinical winner for hexarelin vs ipamorelin either. A familiar collection of peptide names can make the evidence seem more complete than it is.

The reference list contains the record behind this comparison; the effects notes examine what tolerability findings and anecdotal reports can actually support.